Despite the threat of a 200% tariff, most pharma stocks remained stable. US President Donald Trump’s 200% tariff threat on the pharmaceutical industry is a “shock” that will reverberate through global ...

Niagen has secured a worldwide exclusive commercial licence agreement with Haukeland University Hospital to treat Parkinson's disease.

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV capsids.

Global funding cuts, including those made by the Trump administration, are set to increase cases of HIV in Africa, research suggests.

Swissmedic approved the registration of IFINWIL (eflornithine) as a monotherapy to treat paediatric patients with high-risk neuroblastoma, ...

Chugai signed a joint research and licencing agreement with Singapore-based biotechnology firm Gero to create new antibody drug candidates ...

Several medical organisations have filed a lawsuit against RFK Jr and the HHS over recent changes to the US immunisation schedule.

The pulmonary arterial hypertension market is forecast to grow at a CAGR of 2.0% from 2024 to 2034, reaching $9.35bn across 7MM.

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for newborns and young infants. Known as ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease, from Boston Pharmaceuticals ...

The FDA has approved Ekterly (sebetralstat) as the first and only oral on-demand medication for acute attacks of hereditary angioedema (HAE).